メニュー
Recommends testing for acute pituitary insufficiency in all patients with pituitary apoplexy. Use when managing pituitary apoplexy patient; triggers include pituitary apoplexy diagnosis.
デフォルトでは、最初にソースを確認する Prompt が選択されています。直接コマンドに切り替えるか、ローカルコピーをダウンロードすることもできます。
インストールを決める前に、SKILL.md と SkillsMP に表示されている付属ファイルをお読みください。
SOC 職業分類に基づく
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
直接コマンドでは確認用 Prompt が省略されます。実行前にソースを確認してください。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill ata-pituitary-apoplexy-pituitary-insufficiency-testコマンドは1行のまま表示されます。コピー前に横へスクロールして全体を確認してください。
ローカルで確認しますか？SkillsMP が現在取得できるファイルをダウンロードできます。
SKILL.md を表示中
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
| name | ata-pituitary-apoplexy-pituitary-insufficiency-test |
| description | Recommends testing for acute pituitary insufficiency in all patients with pituitary apoplexy. Use when managing pituitary apoplexy patient; triggers include pituitary apoplexy diagnosis. |
Collect clinical history (sudden severe headache, vomiting, visual field deficits, altered mental status) and obtain emergency pituitary MRI to confirm pituitary apoplexy.
If pituitary apoplexy is confirmed by MRI or highly suspected clinically, rule in and proceed to test for acute pituitary insufficiency.
Measure serum cortisol and ACTH; if cortisol is low (<5 µg/dL) or inappropriately normal with low or undetectable ACTH, classify as acute pituitary insufficiency.
Initiate stress-dose glucocorticoids immediately (e.g., hydrocortisone 50-100 mg IV bolus) and adjust doses according to severity of illness and magnitude of the stressor (e.g., 25-75 mg/24h for mild-moderate stress, 100 mg IV bolus + continuous infusion for major stress) while awaiting formal testing, and continue until pituitary function is evaluated.
Do not delay glucocorticoid therapy pending laboratory confirmation of adrenal insufficiency, as this can precipitate adrenal crisis and death; avoid relying solely on random cortisol without clinical context; remember to assess for other pituitary hormone deficiencies (TSH, gonadotropins, GH) after stabilization.
A 55-year-old man presents with sudden occipital headache, nausea, and right-sided weakness. MRI reveals pituitary apoplexy with suprasellar extension. Initial serum cortisol is 4 µg/dL with ACTH <5 pg/mL. He receives hydrocortisone 100 mg IV bolus followed by 50 mg IV every 6 hours (adjusted for major surgical stress), and undergoes urgent neurosurgical decompression.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, doi:10.1210/jc.2016-2118